25家中国内分泌与代谢领域创新药公司获融资!

创鉴汇
25 Jun

内分泌与代谢疾病因患者基数庞大且临床需求持续增长,成为创新药研发的重要方向。据公开数据统计,2025年至今,该领域至少发生25起创新药公司融资事件,已披露融资总额超125亿元。融资覆盖糖尿病、肥胖、高脂血症等疾病,涉及小分子药物、多肽、蛋白质药物及细胞疗法等技术路径。从IPO公司到新锐技术平台,资本正加速涌入这一充满潜力的治疗领域。融资亮点聚焦多肽与蛋白质药物主导代谢性疾病疗法创新:近半数获融资...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10